Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -106.8%
- Operating Margin Trend +238.96 pp/yr
APLS
Apellis Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -222.4%
- 5yr Share-Count CAGR 10.9%
Growth Quality
Weight: 35%
A+
94
- 5yr Revenue CAGR 32.0%
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
D
36
- 5yr FCF Margin -337.6%
- 5yr FCF/NI Conversion 2.01x
Balance Sheet
Weight: 10%
C+
62
- Net Debt / EBITDA 0.26x
- Interest Coverage (EBIT/Int) 1.54x
- Altman Z-Score 2.46
Stability
Weight: 5%
B+
79
- Negative-Revenue Years (5) 1/5
- Piotroski F-Score 7
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.0 of 5 gurus held; 5 full exits.
- Holders
- 0 -5
- Avg Δ position
- —
- New buys
- 0
- Full exits
- 5